Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1413).(02).Dermatology Department Case No (102):-Suspected Scabies with Possible Onychomycosis (1Prescription+0Report+0Image)1199

Prescription attached:-

đŸŠē LIPU MED — Full Clinical Prescription Review & Working Diagnostic Assessment

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻž āĻŦāĻž āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ (Suspected Scabies), āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ (Onychomycosis)āĨ¤ āϚ⧁āϞāĻ•āĻžāύāĻŋāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš (Pruritic Dermatitis) āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϤāĻŦ⧇ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāĻŦāϰāĻŖ āĻ“ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āύāĻž āĻĨāĻžāĻ•āĻžā§Ÿ āĻāϗ⧁āϞ⧋ āύāĻŋāĻļā§āϚāĻŋāϤ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āύ⧟āĨ¤

Clinical Status: Provisional Working Assessment — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟āĨ¤

Prescription date: 02 October 2026

Review date: Wednesday, 21 October 2026

Source: One prescription photograph; no separate laboratory report or clinical skin photograph.

Overall diagnostic confidence: 0.70/1.00

âš ī¸ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Clinical Safety Alert: āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ Cefixime 400 mg āĻĻāĻŋāύ⧇ āĻĻ⧁āĻŦāĻžāϰ, Ivermectin 12 mg āĻāĻ• āĻĻāĻŋāύ āĻĒāϰāĻĒāϰ āĻĒāĻžāρāϚāϟāĻŋ āĻĄā§‹āϜ āĻāĻŦāĻ‚ Permethrin 5% āĻĒāĻžāρāϚ āϰāĻžāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϏāĻžāϧāĻžāϰāĻŖ uncomplicated scabies-āĻāϰ āĻĒā§āϰāϚāϞāĻŋāϤ guideline regimen āĻĨ⧇āϕ⧇ āĻāϗ⧁āϞ⧋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĻ­āĻžāĻŦ⧇ āĻ­āĻŋāĻ¨ā§āύāĨ¤ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻĄā§‹āϜ āĻ“ āϰ⧋āϗ⧇āϰ āϤ⧀āĻŦā§āϰāϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤ āϰ⧋āĻ—ā§€āϕ⧇ āĻĒāϰ⧀āĻ•ā§āώāĻž āύāĻž āĻ•āϰ⧇ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻ…āύ⧁āϏāϰāĻŖ āĻŦāĻž āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻž āύāĻŋāϰāĻžāĻĒāĻĻ āύ⧟āĨ¤


đŸŸĻ SECTION 01 — Website-Verified Case Identification / āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āϕ⧇āϏ āĻĒāϰāĻŋāϚāĻŋāϤāĻŋ

1.1 Website Verification / āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ āϝāĻžāϚāĻžāχ

āφāϜ raiyyantahsan.com-āĻāϰ Medical Blog āĻāĻŦāĻ‚ Dermatology archive āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϤāĻĨā§āϝ:

Verification parameterLatest publishedProposed new case
Total Case (TC)TC (1408)TC (1409)
Department Code (DCS)0202
Dermatology Case No.101102
DepartmentDermatologyDermatology
DiseaseSuspected ScabiesSuspected Scabies with Possible Onychomycosis

āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡āϰ āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ Medical Blog post āĻ›āĻŋāϞ TC(1408), Oncology Case No. 36, āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ 20 October 2026āĨ¤ Dermatology archive-āĻ āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ āϕ⧇āϏ āĻ›āĻŋāϞ TC(1392).(02).Dermatology Department Case No (101)āĨ¤ āϤāĻžāχ āύāϤ⧁āύ āϕ⧇āϏ⧇āϰ āϜāĻ¨ā§āϝ TC(1409), DCS(02), Dermatology Case No (102) āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻāϟāĻŋ āĻāĻ–āύ⧋ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āϕ⧇āϏ āύāĻŽā§āĻŦāϰ āύ⧟; āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āφāϗ⧇ āύāϤ⧁āύ āĻĒā§‹āĻ¸ā§āϟ āĻāϏ⧇āϛ⧇ āĻ•āĻŋ āύāĻž āĻĒ⧁āύāϰāĻžā§Ÿ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Website numbering confidence: 0.96

1.2 Patient Identification / āϰ⧋āĻ—ā§€āϰ āĻĒāϰāĻŋāϚāĻŋāϤāĻŋ

ParameterPrescription findings
Patient name / āύāĻžāĻŽāĻšāĻžāϤ⧇ āϞ⧇āĻ–āĻž; āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ ā§‹āĻĻā§āϧāĻžāϰ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž
Age / āĻŦ⧟āϏ28 years / ā§¨ā§Ž āĻŦāĻ›āϰ
Sex / āϞāĻŋāĻ™ā§āĻ—Not documented / āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Registration No.8663
Visit No.1
Prescription date02/10/2026
PhysicianāĻĄāĻž. āϧ⧀āĻŽāĻžāύ āĻĻ⧇āĻŦāύāĻžāĻĨ
DepartmentDermatology / āϚāĻ°ā§āĻŽāϰ⧋āĻ— āĻŦāĻŋāĻ­āĻžāĻ—
Weight / āĻ“āϜāύNot documented / āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Blood pressureNot documented
Allergy statusNot documented
Pregnancy/lactation statusNot documented

Extraction confidence: 0.98; unreadable patient name: 0.30


đŸŸĻ SECTION 02 — Original Prescription: Complete Clinical Extraction / āĻŽā§‚āϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āϤāĻĨā§āϝ

2.1 C/C — Chief Complaint / āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāϧāĻžāύ āĻ…āĻ­āĻŋāϝ⧋āĻ—

Prescription findings: āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ C/C āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

āϤāĻŦ⧇ āĻ“āώ⧁āϧ āĻ“ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĨ⧇āϕ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ•ā§Ÿā§‡āĻ•āϟāĻŋ āϏāĻŽāĻ¸ā§āϝāĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ•āϰ⧇āϛ⧇āύ āĻŦāϞ⧇ āĻŦā§‹āĻāĻž āϝāĻžā§ŸāĨ¤

Possible clinical complaintāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨEvidence statusConfidence
PruritusāĻ¤ā§āĻŦāϕ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋAtrizin-āĻāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋāϰ āωāĻ˛ā§āϞ⧇āĻ– āĻ°ā§Ÿā§‡āϛ⧇0.95
Scabies-like skin eruptionāĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻžāϰ āĻŽāϤ⧋ āϚāĻ°ā§āĻŽāϰ⧋āĻ—Permethrin āĻ“ Ivermectin prescribed0.82
Nail discoloration or dystrophyāύāϖ⧇āϰ āϰāĻ‚ āĻ“ āĻ—āĻ āύ⧇āϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύNail serum, Clotrimazole āĻ“ Terbinafine prescribed0.70
Possible alopecia/hair concernāϚ⧁āϞ āĻĒ⧜āĻž āĻŦāĻž āϚ⧁āϞ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžHair serum prescribed0.55
Secondary bacterial infectionāĻ¤ā§āĻŦāϕ⧇ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡āϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖAntibiotic prescribed; āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āϞ⧇āĻ–āĻž āύ⧇āχ0.45

Important: āĻāϗ⧁āϞ⧋ āĻ“āώ⧁āϧ āĻĨ⧇āϕ⧇ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϏāĻŽāĻ¸ā§āϝāĻž; āϰ⧋āĻ—ā§€āϰ āϏāϰāĻžāϏāϰāĻŋ āĻŦāĻ°ā§āĻŖāĻŋāϤ C/C āĻšāĻŋāϏ⧇āĻŦ⧇ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

2.2 O/E — On Examination / āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āĻĒā§āϰāĻžāĻĒā§āϤ āϤāĻĨā§āϝ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ O/E āĻļāĻŋāϰ⧋āύāĻžāĻŽ āĻ°ā§Ÿā§‡āϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ examination finding āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Not documented:

  • Skin lesion morphology — āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ⧇āϰ āφāĻ•ā§ƒāϤāĻŋ āĻ“ āϧāϰāύāĨ¤
  • Burrows — āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻŽāĻžāχāĻŸā§‡āϰ āϤ⧈āϰāĻŋ āϏāϰ⧁ āϏ⧁āĻĄāĻŧāĻ™ā§āϗ⧇āϰ āĻŽāϤ⧋ āĻĻāĻžāĻ—āĨ¤
  • Papules — āϛ⧋āϟ āωāρāϚ⧁ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋāĨ¤
  • Excoriations — āϚ⧁āϞāĻ•āĻžāύ⧋āϰ āĻ•āĻžāϰāϪ⧇ āφāρāĻšā§œā§‡āϰ āĻ•ā§āώāϤāĨ¤
  • Pustules — āĻĒ⧁āρāϜāϝ⧁āĻ•ā§āϤ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋāĨ¤
  • Nail examination — āύāϖ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤
  • Scalp examination — āĻŽāĻžāĻĨāĻžāϰ āĻ¤ā§āĻŦāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžāĨ¤

Confidence: 0.99

2.3 Doctor’s Diagnosis — Dx / āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ Dx āĻ…āĻ‚āĻļ⧇ āĻĻ⧁āϟāĻŋ āϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āϞ⧇āĻ–āĻž āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ:

  1. “IS”
  2. “Ony” — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĒāĻžāĻ ā§‹āĻĻā§āϧāĻžāϰ

āĻāĻ–āĻžāύ⧇ “IS” āϏāĻ‚āĻ•ā§āώāĻŋāĻĒā§āϤ āϰ⧂āĻĒāϟāĻŋāϰ āĻĒā§‚āĻ°ā§āĻŖ āĻ…āĻ°ā§āĻĨ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āϤāĻžāχ āĻāϟāĻŋāϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ Infected Scabies āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻšāĻžāϤ⧇ āϞ⧇āĻ–āĻž āĻļāĻŦā§āĻĻāϟāĻŋ “Ony” āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āϝāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• Onychomycosis āĻŦā§‹āĻāĻžāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤ āϤāĻŦ⧇ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻžāϰ āĻ•āĻžāϰāϪ⧇ āĻāϟāĻŋ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Documented diagnosis confidence:

  • “IS” āϞ⧇āĻ–āĻž āφāϛ⧇: 0.95
  • “IS” = Infected Scabies: 0.35
  • “Ony” = Onychomycosis: 0.65

2.4 Investigation / āĻĒāϰ⧀āĻ•ā§āώāĻž

No investigation was prescribed or documented.

āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ CBC, KOH examination, nail microscopy, fungal culture āĻŦāĻž LFT āϕ⧋āύ⧋āϟāĻŋāϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĻ⧇āĻ–āĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤

Confidence: 0.99

2.5 Treatment Plan / āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϞāĻ•ā§āĻˇā§āϝ:

  1. Scabicidal treatment — āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āĻŽāĻžāχāϟ āĻĻā§‚āϰ āĻ•āϰāĻžāĨ¤
  2. Antipruritic treatment — āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ•āĻŽāĻžāύ⧋āĨ¤
  3. Antifungal treatment — āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤
  4. Anti-inflammatory treatment — āĻĒā§āϰāĻĻāĻžāĻš āĻ•āĻŽāĻžāύ⧋āĨ¤
  5. Possible bacterial infection treatment — āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤
  6. Nail and hair supportive care — āύāĻ– āĻ“ āϚ⧁āϞ⧇āϰ āϝāĻ¤ā§āύāĨ¤

Treatment-intent confidence: 0.88


đŸŸĻ SECTION 03 — Patient History Assessment / āϰ⧋āĻ—ā§€āϰ āχāϤāĻŋāĻšāĻžāϏ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŖ history āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

History parameterEnglish meaningPrescription findings
I/HImmunization History — āϟāĻŋāĻ•āĻžāĻĻāĻžāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
O/HObstetric History — āĻ—āĻ°ā§āĻ­āϧāĻžāϰāĻŖ āĻ“ āĻĒā§āϰāϏāĻŦ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
D/HDrug History — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ“āώ⧁āϧ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
M/HMedical History — āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
Surgical HistoryāĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
Family HistoryāĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏN/A
Allergy HistoryāĻ“āώ⧁āϧ āĻŦāĻž āĻ…āĻ¨ā§āϝ āĻ•āĻŋāϛ⧁āϤ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āχāϤāĻŋāĻšāĻžāϏN/A
O/S/EOn Systemic Examination — āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āĻ…āĻ™ā§āĻ—āϤāĻ¨ā§āĻ¤ā§āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžN/A
O/G/EOn General Examination — āϏāĻžāϧāĻžāϰāĻŖ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžN/A

āĻāĻ–āĻžāύ⧇ N/A = Not Available / āϤāĻĨā§āϝ āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤ āĻāϰ āĻ…āĻ°ā§āĻĨ āϰ⧋āĻ—ā§€āϰ āϕ⧋āύ⧋ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āϰ⧋āĻ— āĻŦāĻž āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āύ⧇āĻ‡â€”āĻāĻŽāύ āύ⧟āĨ¤

Confidence: 0.99

Additional History Required / āφāϰāĻ“ āϝ⧇ āχāϤāĻŋāĻšāĻžāϏ āύāĻŋāϤ⧇ āĻšāĻŦ⧇

Scabies evaluation-āĻāϰ āϜāĻ¨ā§āϝ: āϰāĻžāϤ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦāĻžā§œā§‡ āĻ•āĻŋ āύāĻž, āĻāĻ•āχ āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϝāĻĻ⧇āϰ āϚ⧁āϞāĻ•āĻžāύāĻŋ āφāϛ⧇ āĻ•āĻŋ āύāĻž, āφāϙ⧁āϞ⧇āϰ āĻĢāĻžāρāĻ•, āĻ•āĻŦāϜāĻŋ, āϕ⧋āĻŽāϰ, āύāĻžāĻ­āĻŋāϰ āϚāĻžāϰāĻĒāĻžāĻļ āĻŦāĻž āϝ⧌āύāĻžāĻ™ā§āϗ⧇ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ āφāϛ⧇ āĻ•āĻŋ āύāĻž āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

Onychomycosis evaluation-āĻāϰ āϜāĻ¨ā§āϝ: āύāĻ– āĻŽā§‹āϟāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž, āĻšāϞ⧁āĻĻ āĻŦāĻž āϏāĻžāĻĻāĻž āĻšā§Ÿā§‡āϛ⧇ āĻ•āĻŋ āύāĻž, āύāĻ– āϭ⧇āϙ⧇ āϝāĻžā§Ÿ āĻ•āĻŋ āύāĻž, āĻāĻ•āĻžāϧāĻŋāĻ• āύāĻ– āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āφāϗ⧇ āϕ⧋āύ⧋ antifungal āĻ—ā§āϰāĻšāĻŖ āĻ•āϰ⧇āϛ⧇āύ āĻ•āĻŋ āύāĻž āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

Drug safety-āĻāϰ āϜāĻ¨ā§āϝ: Liver disease, kidney disease, diabetes, previous drug allergy, pregnancy possibility āĻāĻŦāĻ‚ āϚāϞāĻŽāĻžāύ āϏāĻŦ āĻ“āώ⧁āϧ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.97


đŸŸĻ SECTION 04 — Physical Examination / āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž

āĻāχ āĻ…āĻ‚āĻļ⧇ āϕ⧋āύ⧋ findings āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤ āύāĻŋāĻšā§‡āϰ examination-āϗ⧁āϞ⧋ āύāϤ⧁āύ āĻ•āϰ⧇ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

ExaminationWhat to look for / āϕ⧀ āĻĻ⧇āĻ–āϤ⧇ āĻšāĻŦ⧇
General examinationTemperature, pulse, BP, hydration
Skin examinationPapules, burrows, excoriations, crusts
Interdigital spacesāφāϙ⧁āϞ⧇āϰ āĻĢāĻžāρāϕ⧇ āĻ•ā§āώ⧁āĻĻā§āϰ āϏ⧁āĻĄāĻŧāĻ™ā§āĻ— āĻŦāĻž āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ
Wrist and waist examinationāĻ•āĻŦāϜāĻŋ āĻ“ āϕ⧋āĻŽāϰ⧇ āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āϏāĻžāϧāĻžāϰāĻŖ āĻ•ā§āώāϤ
Nail examinationThickening, discoloration, onycholysis
Scalp examinationScaling, inflammation, hair thinning
Secondary infection assessmentPus, warmth, tenderness, spreading redness

Burrow / āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āϏ⧁āĻĄāĻŧāĻ™ā§āĻ—: āĻ¤ā§āĻŦāϕ⧇āϰ āĻ“āĻĒāϰ āϏāϰ⧁ āφāρāĻ•āĻžāĻŦāĻžāρāĻ•āĻž āϰ⧇āĻ–āĻž, āϝāĻž āĻ¸ā§āĻ¤ā§āϰ⧀ āĻŽāĻžāχāϟ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ“āĻĒāϰ⧇āϰ āĻ¸ā§āϤāϰ⧇ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻ•āϰāĻžāϰ āϏāĻŽā§Ÿ āϤ⧈āϰāĻŋ āĻ•āϰ⧇āĨ¤

Onycholysis / āύāĻ– āφāϞāĻ—āĻž āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž: Nail plate āϤāĻžāϰ āύāĻŋāĻšā§‡āϰ nail bed āĻĨ⧇āϕ⧇ āφāϞāĻžāĻĻāĻž āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻžāĨ¤

Confidence: 0.97


đŸŸĻ SECTION 05 — Doctor’s Diagnosis & Clinical Impression / āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟ āĻ“ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϧāĻžāϰāĻŖāĻž

đŸŸĸ Suspected Scabies / āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻž

Supporting evidence:

  • Perosa 5% contains Permethrin, a scabicidal agent.
  • Alice 12 mg contains Ivermectin, also used to treat scabies.
  • Atrizin prescribed for itching.

āĻāχ āϤāĻŋāύāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ āϏāĻŽāĻ¨ā§āĻŦ⧟ āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤ āϤāĻŦ⧇ āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ burrow, characteristic rash āĻŦāĻž āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦā§āϝāĻ•ā§āϤāĻŋāϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

Confidence that the physician intended scabies treatment: 0.90

Confidence that the patient truly has scabies: 0.70

🟠 Possible Onychomycosis / āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Supporting evidence:

  • Fungiben 250 — Terbinafine.
  • Clarizol solution — Clotrimazole.
  • Nailcis serum — nail-care product.
  • Possible handwritten “Ony”.

āĻāχ āĻ“āώ⧁āϧāϗ⧁āϞ⧋ āύāϖ⧇āϰ fungal infection-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻŦāĻž supportive care-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.72

🟠 Possible Secondary Dermatitis / āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚ⧁āϞāĻ•āĻžāύāĻŋāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš

Cetirizine āĻāĻŦāĻ‚ Methylprednisolone āĻĻ⧇āĻ“ā§ŸāĻžāϰ āĻ•āĻžāϰāϪ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ“ āĻĒā§āϰāĻĻāĻžāĻš āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.62

🟠 Possible Secondary Bacterial Infection / āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡āϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ

Cefixime āĻ“ Gentamicin-containing cream āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒ⧁āρāϜ, āĻœā§āĻŦāϰ, spreading erythema āĻŦāĻž cellulitis-āĻāϰ āϕ⧋āύ⧋ āĻŦāĻ°ā§āĻŖāύāĻž āύ⧇āχāĨ¤

Confidence: 0.45


đŸŸĻ SECTION 06 — Investigations / āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ āĻĒāϰ⧀āĻ•ā§āώāĻž-āύāĻŋāϰ⧀āĻ•ā§āώāĻž

6.1 Doctor-Advised Investigations / āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž

None documented / āϕ⧋āύ⧋ āĻĒāϰ⧀āĻ•ā§āώāĻž āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

6.2 My Recommended Investigations / āφāĻŽāĻžāϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āĻĒāϰ⧀āĻ•ā§āώāĻž

InvestigationPurpose / āϕ⧇āύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύPriority
Skin examination with dermoscopyScabies burrow āĻ“ mite āĻļāύāĻžāĻ•ā§āϤHigh
Skin scraping microscopyāĻŽāĻžāχāϟ, āĻĄāĻŋāĻŽ āĻŦāĻž āĻŽāϞ⧇āϰ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤāĻŋ āĻļāύāĻžāĻ•ā§āϤWhen indicated
Nail clipping for KOH microscopyāύāϖ⧇ fungal elements āĻļāύāĻžāĻ•ā§āϤHigh before systemic antifungal
Nail fungal culture or PAS histologyFungal diagnosis confirmationWhen indicated
ALT, AST, bilirubinOral terbinafine-āĻāϰ āφāϗ⧇ liver assessmentHigh
CBCāĻŦā§āϝāĻžāĻĒāĻ• āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻŦāĻž āĻŦāĻŋāĻļ⧇āώ clinical concern āĻĨāĻžāĻ•āϞ⧇Conditional
Renal functionāĻŦāĻŋāĻļ⧇āώ āĻā§āρāĻ•āĻŋ āĻŦāĻž āĻ“āώ⧁āϧ⧇āϰ āĻĄā§‹āϜ āϏāĻŽāĻ¨ā§āĻŦā§Ÿā§‡āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϞ⧇Conditional
Bacterial cultureāĻĒ⧁āρāϜāϝ⧁āĻ•ā§āϤ, recurrent āĻŦāĻž treatment-resistant infection āĻšāϞ⧇Conditional

Clinical interpretation: Scabies āϏāĻžāϧāĻžāϰāĻŖāϤ history, examination āĻ“ dermoscopy āĻĻāĻŋā§Ÿā§‡ āύāĻŋāĻ°ā§āϪ⧟ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤ Negative skin scraping āĻĻāĻŋā§Ÿā§‡ āϏāĻŦāϏāĻŽā§Ÿ scabies āĻŦāĻžāĻĻ āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤ Onychomycosis-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ systemic antifungal āĻļ⧁āϰ⧁ āĻ•āϰāĻžāϰ āφāϗ⧇ fungal confirmation āĻŦāĻŋāĻļ⧇āώ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Confidence: 0.97


🟩 SECTION 07 — Prescribed Drug Analysis — MedEx āĻ…āύ⧁āϝāĻžā§Ÿā§€ / āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻŽā§‹āϟ ā§§ā§§āϟāĻŋ āĻ“āώ⧁āϧ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϏāĻžāĻŽāĻ—ā§āϰ⧀ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ MedEx-āĻ āĻĒāĻžāĻ“ā§ŸāĻž drug information āĻāĻŦāĻ‚ āϝ⧇āϏāĻŦ āĻĒāĻŖā§āϝ MedEx-āĻ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋ, āϏ⧇āϗ⧁āϞ⧋āϰ āĻĒ⧃āĻĨāĻ• āϤāĻĨā§āϝ āύāĻŋāĻšā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϞ⧋āĨ¤

7.1 Complete Prescribed Medicine Table / āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻ“āώ⧁āϧ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž

No.BrandGeneric / CompositionPrescription instructionDuration
1Cefim-3 400Cefixime 400 mg1+0+17 days
2Atrizin 10Cetirizine 10 mg0+0+1; itching worse āĻšāϞ⧇1 month
3Prickly Heat SoapMedicated cooling soapDaily bathing1 month
4Alice 12Ivermectin 12 mg1 tablet every alternate day5 tablets
5Solupred 8Methylprednisolone 8 mg1+0+15 days
6Combiderm CreamBetamethasone + Clotrimazole + GentamicinTwice daily on affected areas if sores1 month
7Clarizol SolutionClotrimazole 1%Morning and evening on affected nailsContinue
8Nailcis SerumNail repair serumEvery night on affected nailsContinue
9Fungiben 250Terbinafine 250 mg0+0+12 months
10Reona Hair SerumHair-care serumScalp massage at night2 months
11Perosa 5% CreamPermethrin 5%Whole-body application on specified nights2 months printed; 5 applications specified

Medicine 01 — Cefim-3 400

  1. Generic name: Cefixime Trihydrate — āϏ⧇āĻĢāĻŋāĻ•ā§āϏāĻŋāĻŽāĨ¤
  2. Brand name: Prescription: Cefim-3 400; MedEx-āĻ matching capsule listed as Cefim-3 DS 400.
  3. MedEx alternate brands: Cef-3 DS, Cefimax, CefiximāĨ¤
  4. MedEx Therapeutic Class: Third generation cephalosporins — āϤ⧃āĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ āϏ⧇āĻĢāĻžāϞ⧋āĻ¸ā§āĻĒā§‹āϰāĻŋāύāĨ¤
  5. Pharmacological Class: β-lactam antibiotic — āĻŦāĻŋāϟāĻž-āĻ˛ā§āϝāĻžāĻ•āϟāĻžāĻŽ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ•āĨ¤
  6. Use of purpose: Susceptible bacterial infections — āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤
  7. Why prescribed in this patient: Secondary bacterial infection āϏāĻ¨ā§āĻĻ⧇āĻšā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇; āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύ⧇āχāĨ¤
  8. Side effects: Diarrhoea, abdominal pain, nausea, rash, allergy; rarely severe antibiotic-associated colitisāĨ¤
  9. MedEx link: Cefim-3 DS 400 mg — MedEx
  10. Unit and strip price: Capsule ā§ŗ60; 7-capsule strip ā§ŗ420āĨ¤ Other forms: 200 mg capsule, 400 mg tablet, suspension and pediatric dropsāĨ¤
  11. Mechanism: Bacterial cell-wall synthesis inhibition — āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϰ āϕ⧋āώāĻĒā§āϰāĻžāĻšā§€āϰ āϤ⧈āϰāĻŋ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇āĨ¤
  12. Indications: Selected respiratory, urinary and other susceptible bacterial infectionsāĨ¤
  13. Interactions + contraindications: Cephalosporin allergy; warfarin āĻŦāĻž anticoagulant-āĻāϰ āϏāĻ™ā§āϗ⧇ bleeding risk āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ; renal impairment-āĻ dose adjustment āϞāĻžāĻ—āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  14. Precautions: āĻ…āϝāĻĨāĻž antibiotic āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϞ⧇ resistance āĻ“ adverse effects āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  15. Dosage: āϏāĻžāϧāĻžāϰāĻŖ adult dosage 200–400 mg/day, infection āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻāĻ•āĻŦāĻžāϰ āĻŦāĻž āĻĻ⧁āχ āĻ­āĻžāϗ⧇āĨ¤ Prescription-āĻāϰ 400 mg twice daily = 800 mg/day, āϝāĻž āϏāĻžāϧāĻžāϰāĻŖ recommended daily dose-āĻāϰ āĻĻā§āĻŦāĻŋāϗ⧁āĻŖāĨ¤ āϜāϰ⧁āϰāĻŋ dose verification āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  16. Pregnancy & lactation: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ›āĻžā§œāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āύ⧟; prescriber-āĻāϰ individual risk–benefit assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Drug identification confidence: 0.98; patient-specific indication: 0.45.

Medicine 02 — Atrizin 10 mg

  1. Generic name: Cetirizine Hydrochloride — āϏ⧇āϟāĻŋāϰāĻŋāϜāĻŋāύāĨ¤
  2. Brand name: Atrizin 10, BeximcoāĨ¤
  3. Alternate brands: Arcet, Alatrol āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ Cetirizine brandsāĨ¤
  4. MedEx Therapeutic Class: Anti-histamine — āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤
  5. Pharmacological Class: Second-generation H1 receptor antagonistāĨ¤
  6. Purpose: Itching, urticaria and allergic symptoms āĻ•āĻŽāĻžāύ⧋āĨ¤
  7. Why prescribed: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦ⧇āĻļāĻŋ āĻšāϞ⧇ āϏ⧇āĻŦāύ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ Scabies-associated itch āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  8. Side effects: Drowsiness, dry mouth, fatigue, headacheāĨ¤
  9. MedEx link: Atrizin 10 mg — MedEx
  10. Price: ā§ŗ3/tablet; 15-tablet strip ā§ŗ45āĨ¤ Other compositions: 5 mg/5 ml syrup āĻāĻŦāĻ‚ 2.5 mg/ml dropsāĨ¤
  11. Mechanism: Histamine H1 receptor blockade — āĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύ⧇āϰ āĻĒā§āϰāĻ­āĻžāĻŦ āĻ•āĻŽāĻžā§ŸāĨ¤
  12. Indications: Allergic rhinitis, urticaria āĻ“ allergic pruritusāĨ¤
  13. Interactions + contraindications: Cetirizine allergy; alcohol āĻ“ sedating medicines-āĻāϰ āϏāĻ™ā§āϗ⧇ āϘ⧁āĻŽāĻ­āĻžāĻŦ āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  14. Precautions: Renal impairment-āĻ dose adjustment āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  15. Dosage: Adult standard dose 10 mg once daily; prescribed āϰāĻžāϤ⧇ āĻāĻ•āϟāĻŋāĨ¤
  16. Pregnancy & lactation: Pregnancy-āϤ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž; breast milk-āĻ āϝāĻžā§Ÿ, āϤāĻžāχ lactation-āĻ āϏāϤāĻ°ā§āĻ•āϤāĻžāĨ¤

Confidence: 0.98

Medicine 03 — Prickly Heat Soap

  1. Generic name: Medicated cooling soap; āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ pharmaceutical generic āύ⧇āχāĨ¤
  2. Brand: Prickly Heat SoapāĨ¤
  3. MedEx alternate brand: Not verified — MedEx-āĻ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ listing āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤
  4. Therapeutic Class: MedEx therapeutic class unavailableāĨ¤
  5. Pharmacological Class: Skin cleanser/cooling preparationāĨ¤
  6. Purpose: āĻ¤ā§āĻŦāĻ• āĻĒāϰāĻŋāĻˇā§āĻ•āĻžāϰ āϰāĻžāĻ–āĻž, prickling āĻŦāĻž itching sensation āĻ•āĻŽāĻžāύ⧋āĨ¤
  7. Why prescribed: āϚ⧁āϞāĻ•āĻžāύāĻŋāϝ⧁āĻ•ā§āϤ āĻ¤ā§āĻŦāϕ⧇ supportive hygiene-āĻāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇āĨ¤
  8. Side effects: Skin dryness, irritation, contact dermatitisāĨ¤
  9. MedEx link: Not available; Prickly Heat Soap product information
  10. Price: āĻāĻ•āϟāĻŋ 75 g product listing-āĻ āĻĒā§āϰāĻžā§Ÿ ā§ŗ732 MRP āĻĻ⧇āĻ–āĻž āϝāĻžā§Ÿ; retailer āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĻāĻžāĻŽ āĻ­āĻŋāĻ¨ā§āύāĨ¤
  11. Mechanism: Cleansing āĻāĻŦāĻ‚ menthol/camphor-āϜāĻžāĻ¤ā§€ā§Ÿ āωāĻĒāĻžāĻĻāĻžāύ⧇āϰ cooling sensationāĨ¤ Exact formula product label āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤
  12. Indications: Prickly heat āĻ“ itching-āĻāϰ supportive relief; āĻāϟāĻŋ scabies mite eradication treatment āύ⧟āĨ¤
  13. Interactions + contraindications: Fragrance āĻŦāĻž āωāĻĒāĻžāĻĻāĻžāύāϜāύāĻŋāϤ sensitivity āĻĨāĻžāĻ•āϞ⧇ āĻā§œāĻŋā§Ÿā§‡ āϚāϞāĻžāĨ¤
  14. Precautions: āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϏ⧁āĻ—āĻ¨ā§āϧāĻŋ āĻŦāĻž irritating soap dermatitis āĻŦāĻžā§œāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  15. Dosage: Prescription āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĻ⧈āύāĻŋāĻ• āĻ—ā§‹āϏāϞāĨ¤
  16. Pregnancy & lactation: Exact formulation āĻ…āύ⧁āϝāĻžā§Ÿā§€ safety āĻŦāĻŋāĻŦ⧇āϚāύāĻžāĨ¤

Confidence: 0.80; exact product formulation: 0.65.

Medicine 04 — Alice 12 mg

  1. Generic name: Ivermectin — āφāχāĻ­āĻžāϰāĻŽā§‡āĻ•āϟāĻŋāύāĨ¤
  2. Brand: Alice 12, Square PharmaceuticalsāĨ¤
  3. MedEx alternate brands: A-Mectin, AvemecāĨ¤
  4. MedEx Therapeutic Class: Anthelmintic — āĻĒāϰāĻœā§€āĻŦā§€āύāĻžāĻļāĻ•āĨ¤
  5. Pharmacological Class: Avermectin antiparasiticāĨ¤
  6. Purpose: Scabies mite āĻ“ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰāĻœā§€āĻŦā§€ āĻĻā§‚āϰ āĻ•āϰāĻžāĨ¤
  7. Why prescribed: āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝāĨ¤
  8. Side effects: Nausea, dizziness, diarrhoea, rash; rare neurological reactionsāĨ¤
  9. MedEx link: Alice 12 mg — MedEx
  10. Price: ā§ŗ20/tablet; 10-tablet strip ā§ŗ200āĨ¤ Other composition: 6 mg tabletāĨ¤
  11. Mechanism: Parasite glutamate-gated chloride channels-āĻ āĻ•āĻžāϜ āĻ•āϰ⧇ paralysis āϘāϟāĻžā§ŸāĨ¤
  12. Indications: Scabies, strongyloidiasis, onchocerciasis, selected parasitic infestationsāĨ¤
  13. Interactions + contraindications: Hypersensitivity; anticoagulants āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ interacting medicines review āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  14. Precautions: āĻļāϰ⧀āϰ⧇āϰ āĻ“āϜāύ āύāĻž āĻœā§‡āύ⧇ fixed dose āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤
  15. Dosage: CDC āĻ…āύ⧁āϝāĻžā§Ÿā§€ classic scabies-āĻ 200 micrograms/kg per dose, āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĄā§‹āϜ āϏāĻžāϧāĻžāϰāĻŖāϤ 7–14 āĻĻāĻŋāύ āĻĒāϰ⧇āĨ¤ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ 12 mg āĻāĻ• āĻĻāĻŋāύ āĻĒāϰāĻĒāϰ āĻŽā§‹āϟ āĻĒāĻžāρāϚāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āϞ⧇āĻ–āĻž āφāϛ⧇āĨ¤ āĻāϟāĻŋ routine classic scabies regimen āύ⧟āĨ¤ Severe āĻŦāĻž crusted scabies-āĻ āĻ­āĻŋāĻ¨ā§āύ multiple-dose regimen āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϤāĻžāϰ āϕ⧋āύ⧋ clinical evidence āĻāĻ–āĻžāύ⧇ āύ⧇āχāĨ¤
  16. Pregnancy & lactation: Pregnancy-āϤ⧇ safety established āύ⧟; breastfeeding-āĻ clinical evaluation āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Drug confidence: 0.99; appropriateness of prescribed schedule: uncertain, requires review.

Medicine 05 — Solupred 8 mg

  1. Generic: Methylprednisolone — āĻŽāĻŋāĻĨāĻžāχāϞāĻĒā§āϰ⧇āĻĄāύāĻŋāϏ⧋āϞ⧋āύāĨ¤
  2. Brand: Solupred 8, ZiskaāĨ¤
  3. Alternate brands: Depomed, MedrolāĨ¤
  4. MedEx Therapeutic Class: Glucocorticoids — āĻ—ā§āϞ⧁āϕ⧋āĻ•āĻ°ā§āϟāĻŋāĻ•ā§Ÿā§‡āĻĄāĨ¤
  5. Pharmacological Class: Systemic corticosteroidāĨ¤
  6. Purpose: Inflammation āĻāĻŦāĻ‚ immune-mediated symptoms āĻ•āĻŽāĻžāύ⧋āĨ¤
  7. Why prescribed: āϤ⧀āĻŦā§āϰ inflammatory itching āĻŦāĻž dermatitis āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  8. Side effects: Gastric irritation, increased blood glucose, sleep disturbance, mood changes, infection susceptibilityāĨ¤
  9. MedEx link: Solupred 8 mg — MedEx
  10. Price: ā§ŗ9.50/tablet; 10-tablet strip ā§ŗ95āĨ¤ Other strengths: 2, 4, 16 mgāĨ¤
  11. Mechanism: Glucocorticoid receptor activation āĻāĻŦāĻ‚ inflammatory gene signalling modulationāĨ¤
  12. Indications: Selected inflammatory, allergic, autoimmune and other steroid-responsive disordersāĨ¤
  13. Interactions + contraindications: Active untreated systemic fungal infection, serious infection-related concerns; NSAIDs āĻ“ antidiabetic medicines-āĻāϰ āϏāĻ™ā§āϗ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ interaction āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  14. Precautions: Systemic steroid uncomplicated scabies-āĻāϰ routine treatment āύ⧟āĨ¤ Infection masking, worsening fungal disease āĻāĻŦāĻ‚ immunosuppression-āĻāϰ āĻā§āρāĻ•āĻŋ āφāϛ⧇āĨ¤
  15. Dosage: Prescription: 8 mg twice daily for five daysāĨ¤ āĻāϟāĻŋ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ clinical assessment āĻ›āĻžā§œāĻž āωāĻĒāϝ⧁āĻ•ā§āϤ āĻ•āĻŋ āύāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤
  16. Pregnancy & lactation: Individual risk–benefit assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Drug confidence: 0.99; indication confidence: 0.55.

Medicine 06 — Combiderm Cream

  1. Generic: Betamethasone + Clotrimazole + GentamicināĨ¤
  2. Brand: CombidermāĨ¤
  3. Alternate brands: Aristoderm, Bet-CG, Betson-CG, TrioskināĨ¤
  4. MedEx Therapeutic Class: Betamethasone & Combined preparationsāĨ¤
  5. Pharmacological Class: Corticosteroid + Azole antifungal + Aminoglycoside antibioticāĨ¤
  6. Purpose: Selected inflammatory dermatoses with bacterial or fungal complicationsāĨ¤
  7. Why prescribed: āĻ¤ā§āĻŦāϕ⧇ āĻ•ā§āώāϤ āĻŦāĻž secondary infection-āĻāϰ āϏāĻ¨ā§āĻĻ⧇āĻšā§‡āĨ¤
  8. Side effects: Burning, irritation, skin thinning, hypopigmentation; prolonged steroid use-āĻ skin atrophyāĨ¤
  9. MedEx link: Combiderm composition and MedEx brands
  10. Price: 15 g tube ā§ŗ75āĨ¤ Composition: Betamethasone 0.05% + Clotrimazole 1% + Gentamicin 0.1%āĨ¤
  11. Mechanism: Betamethasone inflammation āĻ•āĻŽāĻžā§Ÿ; Clotrimazole fungal ergosterol synthesis āĻŦāĻžāϧāĻž āĻĻā§‡ā§Ÿ; Gentamicin bacterial protein synthesis āĻŦāĻžāϧāĻž āĻĻā§‡ā§ŸāĨ¤
  12. Indications: Selected steroid-responsive infected dermatosesāĨ¤
  13. Interactions + contraindications: Component hypersensitivity; other corticosteroid products-āĻāϰ āϏāĻ™ā§āϗ⧇ combined exposure āĻŦāĻžā§œā§‡āĨ¤
  14. Precautions: āĻāĻ• āĻŽāĻžāϏ āϧāϰ⧇ steroid-combination cream āĻŦā§āϝāĻŦāĻšāĻžāϰ skin atrophy āĻ“ tinea incognito-āĻāϰ āĻā§āρāĻ•āĻŋ āϤ⧈āϰāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻŽā§āĻ–, skin folds āĻāĻŦāĻ‚ genital area-āϤ⧇ āĻŦāĻŋāĻļ⧇āώ āϏāϤāĻ°ā§āĻ•āϤāĻžāĨ¤
  15. Dosage: Prescription: affected area-āϤ⧇ twice daily, āĻāĻ• āĻŽāĻžāϏāĨ¤ Duration āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  16. Pregnancy & lactation: Extensive āĻŦāĻž prolonged application āĻā§œāĻžāύ⧋; breastfeeding-āĻāϰ āφāϗ⧇ clinical evaluationāĨ¤

Confidence: 0.97

Medicine 07 — Clarizol Solution

  1. Generic: Clotrimazole 1% — āĻ•ā§āϞ⧋āĻŸā§āϰāĻŋāĻŽāĻžāϜāϞāĨ¤
  2. Brand: Clarizol, InceptaāĨ¤
  3. Alternate brands: Dermasim topical solution, Trimazole solutionāĨ¤
  4. MedEx Therapeutic Class: Drugs for subcutaneous and mycoses; Topical Antifungal preparationsāĨ¤
  5. Pharmacological Class: Imidazole antifungalāĨ¤
  6. Purpose: Superficial fungal infectionāĨ¤
  7. Why prescribed: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāϖ⧇āϰ fungal infection āĻŦāĻž nail-fold fungal involvement-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āϜāĻ¨ā§āϝāĨ¤
  8. Side effects: Local burning, redness, irritationāĨ¤
  9. MedEx link: Clarizol 1% Solution — MedEx
  10. Price: 20 ml bottle ā§ŗ68āĨ¤ Also available as 1% creamāĨ¤
  11. Mechanism: Fungal ergosterol synthesis inhibitionāĨ¤
  12. Indications: Dermatophytosis, candidiasis, fungal skin infection; periungual fungal infection-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  13. Interactions + contraindications: Clotrimazole hypersensitivity; topical interaction evidence āϏ⧀āĻŽāĻŋāϤāĨ¤
  14. Precautions: āϏāĻžāϧāĻžāϰāĻŖ clotrimazole solution nail plate-āĻāϰ āϭ⧇āϤāϰ⧇ āϝāĻĨ⧇āĻˇā§āϟ penetration āύāĻžāĻ“ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ Confirmed extensive onychomycosis-āĻāϰ āϜāĻ¨ā§āϝ āĻāϟāĻŋ āĻāĻ•āĻ•āĻ­āĻžāĻŦ⧇ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύ⧟āĨ¤
  15. Dosage: Prescription: affected nails-āĻ āϏāĻ•āĻžāϞ⧇ āĻ“ āĻŦāĻŋāϕ⧇āϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āĻ—, continueāĨ¤
  16. Pregnancy & lactation: āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϏ⧀āĻŽāĻŋāϤ topical use āĻŦāĻŋāĻŦ⧇āϚāύāĻžāĨ¤

Confidence: 0.98

Medicine 08 — Nailcis Serum

  1. Generic: No established single pharmaceutical genericāĨ¤
  2. Brand: CISDERMA Nailcis Nail Repair SerumāĨ¤
  3. MedEx alternate brand: Not verifiedāĨ¤
  4. MedEx Therapeutic Class: Not listed/verifiedāĨ¤
  5. Pharmacological Class: Cosmetic/cosmeceutical nail-care preparationāĨ¤
  6. Purpose: Nail discoloration, brittleness āĻ“ nail-care supportāĨ¤
  7. Why prescribed: āύāϖ⧇āϰ āĻ—āĻ āύ āĻ“ āϰāĻ‚ āωāĻ¨ā§āύāϤ āĻ•āϰāĻžāϰ supportive treatment āĻšāĻŋāϏ⧇āĻŦ⧇āĨ¤
  8. Side effects: Possible contact irritation or allergyāĨ¤
  9. MedEx link: No verified MedEx listingāĨ¤ Manufacturer/product information
  10. Price: 15 ml product retailer listing approximately ā§ŗ1,280; āĻ…āĻ¨ā§āϝ retailer-āĻ MRP ā§ŗ1,380āĨ¤
  11. Mechanism: Product-specific ingredients āĻ…āύ⧁āϝāĻžā§Ÿā§€ nail hydration, exfoliation āĻŦāĻž conditioningāĨ¤ Manufacturing and retailer ingredient lists differ; exact label āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
  12. Indications: Cosmetic nail repair support; clinically proven stand-alone antifungal cure āύ⧟āĨ¤
  13. Interactions + contraindications: Ingredient hypersensitivity; damaged nail āĻŦāĻž surrounding skin-āĻ irritation āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  14. Precautions: Confirmed onychomycosis-āĻāϰ evidence-based antifungal therapy-āĻāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āύ⧟āĨ¤
  15. Dosage: Prescription āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϰāĻžāϤ⧇ affected nails-āĻ āĻĒā§āĻ°ā§Ÿā§‹āĻ—āĨ¤
  16. Pregnancy & lactation: Exact formulation āϜāĻžāύāĻž āĻ›āĻžā§œāĻž āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ safety conclusion āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Product identity confidence: 0.90; formulation confidence: 0.55.

Medicine 09 — Fungiben 250 mg

  1. Generic: Terbinafine Hydrochloride — āϟāĻžāϰāĻŦāĻŋāύāĻžāĻĢāĻŋāύāĨ¤
  2. Brand: Fungiben 250, Derma PharmaceuticalsāĨ¤
  3. Alternate brands: Mycocure, Mycofin, MycofreeāĨ¤
  4. MedEx Therapeutic Class: Other Antifungal preparations, Topical Antifungal preparations — MedEx monograph-āĻāϰ listed classificationāĨ¤
  5. Pharmacological Class: Allylamine antifungalāĨ¤
  6. Purpose: Dermatophyte fungal infection eradicationāĨ¤
  7. Why prescribed: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ onychomycosis-āĻāϰ systemic treatmentāĨ¤
  8. Side effects: Gastrointestinal upset, taste disturbance, rash, abnormal liver enzymes; rarely serious liver injuryāĨ¤
  9. MedEx link: Fungiben 250 mg — MedEx
  10. Price: ā§ŗ60/tablet; 10-tablet strip ā§ŗ600āĨ¤ Other form: Terbinafine 1% creamāĨ¤
  11. Mechanism: Fungal squalene epoxidase inhibitionāĨ¤
  12. Indications: Dermatophyte onychomycosis āĻāĻŦāĻ‚ selected skin fungal infectionsāĨ¤
  13. Interactions + contraindications: Active/chronic liver disease; CYP2D6-metabolized medicines, including selected antidepressants and beta-blockers, require interaction reviewāĨ¤
  14. Precautions: Oral terbinafine āĻļ⧁āϰ⧁ āĻ•āϰāĻžāϰ āφāϗ⧇ baseline ALT/AST āĻāĻŦāĻ‚ liver disease assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤ Dark urine, jaundice āĻŦāĻž persistent nausea āĻšāϞ⧇ urgent medical reviewāĨ¤
  15. Dosage: Adult onychomycosis: 250 mg once daily, typically 6 weeks for fingernails āĻāĻŦāĻ‚ 12 weeks for toenailsāĨ¤ Prescription-āĻ āĻĻ⧁āχ āĻŽāĻžāϏ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇; āϕ⧋āύ āύāĻ– āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āϤāĻž āϜāĻžāύāĻž āύāĻž āĻĨāĻžāĻ•āĻžā§Ÿ duration-āĻāϰ āϝāĻĨāĻžāĻ°ā§āĻĨāϤāĻž āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤
  16. Pregnancy & lactation: Pregnancy-āϤ⧇ initiation generally postponed; oral terbinafine breastfeeding-āĻ recommended āύ⧟āĨ¤

Drug confidence: 0.99; indication confidence: 0.78.

Medicine 10 — Reona Hair Serum

  1. Generic: No established pharmaceutical genericāĨ¤
  2. Brand: Reona Hair SerumāĨ¤
  3. MedEx alternate brand: Not verifiedāĨ¤
  4. MedEx Therapeutic Class: Not availableāĨ¤
  5. Pharmacological Class: Hair-care/cosmetic preparationāĨ¤
  6. Purpose: Hair conditioning, scalp-care supportāĨ¤
  7. Why prescribed: āϚ⧁āϞ⧇āϰ āϕ⧋āύ⧋ āϏāĻŽāĻ¸ā§āϝāĻžāϰ supportive care-āĻāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇; hair-loss diagnosis āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤
  8. Side effects: Possible irritation, contact allergyāĨ¤
  9. MedEx link: No verified MedEx listingāĨ¤ Reona Hair Serum product information
  10. Price: āĻāĻ•āϟāĻŋ 100 ml retailer listing-āĻ āĻĒā§āϰāĻžā§Ÿ ā§ŗ2,375āĨ¤ Product variant āĻ“ seller āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻĻāĻžāĻŽ āĻ­āĻŋāĻ¨ā§āύāĨ¤
  11. Mechanism: Exact formulation verified āύ⧟; cosmetic conditioning effect expectedāĨ¤
  12. Indications: Hair dryness or cosmetic hair-care concern; androgenetic alopecia-āĻāϰ established treatment āύ⧟āĨ¤
  13. Interactions + contraindications: Ingredient sensitivity; topical scalp products-āĻāϰ āϏāĻ™ā§āϗ⧇ irritation āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  14. Precautions: āϚ⧁āϞ āĻĒ⧜āĻžāϰ āĻ•āĻžāϰāĻŖ āύāĻŋāĻ°ā§āϪ⧟ āĻ›āĻžā§œāĻž āĻāϟāĻŋ disease-specific therapy āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤
  15. Dosage: Prescription: āϰāĻžāϤ⧇ scalp-āĻ massage āĻ•āϰ⧇ āĻĒā§āĻ°ā§Ÿā§‹āĻ—, āĻĻ⧁āχ āĻŽāĻžāϏāĨ¤
  16. Pregnancy & lactation: Exact ingredients āϝāĻžāϚāĻžāχ āύāĻž āĻ•āϰ⧇ safety āύāĻŋāĻļā§āϚāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.80; specific formulation confidence: 0.50.

Medicine 11 — Perosa 5% Cream

  1. Generic: Permethrin 5% — āĻĒāĻžāϰāĻŽā§‡āĻĨā§āϰāĻŋāύāĨ¤
  2. Brand: Perosa, Eskayef PharmaceuticalsāĨ¤
  3. Alternate brands: Scabex, Permin, Permisol, PerscabāĨ¤
  4. MedEx Therapeutic Class: Parasiticidal preparationsāĨ¤
  5. Pharmacological Class: Synthetic pyrethroid scabicideāĨ¤
  6. Purpose: Scabies mites eradicationāĨ¤
  7. Why prescribed: āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ scabies treatment-āĻāϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻ“āώ⧁āϧāĨ¤
  8. Side effects: Burning, stinging, itching, erythemaāĨ¤
  9. MedEx link: Perosa 5% Cream — MedEx
  10. Price: 30 g tube ā§ŗ55āĨ¤
  11. Mechanism: Mite neuronal sodium channels-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻŦā§āϝāĻžāĻšāϤ āĻ•āϰ⧇ paralysis āĻāĻŦāĻ‚ death āϘāϟāĻžā§ŸāĨ¤
  12. Indications: Scabies āĻāĻŦāĻ‚ selected ectoparasitic infestationsāĨ¤
  13. Interactions + contraindications: Pyrethroid āĻŦāĻž formulation component hypersensitivityāĨ¤
  14. Precautions: āĻšā§‹āĻ–, āĻŽā§āϖ⧇āϰ āϭ⧇āϤāϰ āĻ“ mucosal surfaces āĻā§œāĻžāϤ⧇ āĻšāĻŦ⧇; excessive applications skin irritation āĻŦāĻžā§œāĻžā§ŸāĨ¤
  15. Dosage: Prescription-āĻ āϰāĻžāϤ⧇ neck-to-toes application āĻāĻŦāĻ‚ ā§§āĻŽ, ⧍⧟, ā§­āĻŽ, ā§§ā§ĒāϤāĻŽ āĻ“ ⧍⧧āϤāĻŽ āϰāĻžāϤ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϏāĻžāϧāĻžāϰāĻŖ classic scabies-āĻ guideline āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻāĻ•āϟāĻŋ application, āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ āĻĒā§āϰāĻžā§Ÿ 7 āĻĻāĻŋāύ āĻĒāϰ⧇ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ application; 8–14 āϘāĻŖā§āϟāĻž āĻĒāϰ⧇ āĻ§ā§ā§Ÿā§‡ āĻĢ⧇āϞāϤ⧇ āĻšā§ŸāĨ¤ āĻĒāĻžāρāϚāĻŦāĻžāϰ application routine regimen āύ⧟; severe āĻŦāĻž crusted scabies āĻĨāĻžāĻ•āϞ⧇ āφāϞāĻžāĻĻāĻž specialist protocol āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  16. Pregnancy & lactation: Pregnancy-āϤ⧇ topical permethrin āϏāĻžāϧāĻžāϰāĻŖāϤ preferred scabies treatments-āĻāϰ āĻāĻ•āϟāĻŋ, āϤāĻŦ⧇ individual clinical assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.99


🩷 SECTION 08 — Bangladesh Clinical Practice: MedEx-Based Drug Options / āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ⧇āϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϤāĻžāϞāĻŋāĻ•āĻž

āύāĻŋāĻšā§‡āϰ āĻ“āώ⧁āϧāϗ⧁āϞ⧋ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇āϰ āĻŦāĻžāϜāĻžāϰ⧇ MedEx-listed optionsāĨ¤ āĻāϗ⧁āϞ⧋ āϏāĻŦ āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž āύ⧟āĨ¤

No.Clinical purposeGenericBangladesh brand examplesClinical rationale
1Classic scabiesPermethrin 5%Perosa, Scabex, PermināĻŽāĻžāχāϟ āύāĻŋāĻ°ā§āĻŽā§‚āϞ
2Selected scabies casesIvermectinAlice, A-Mectin, AvemecSystemic antiparasitic
3Symptomatic itchingCetirizineAtrizin, ArcetāϚ⧁āϞāĻ•āĻžāύāĻŋāϰ āωāĻĒāĻļāĻŽ
4Confirmed onychomycosisTerbinafineFungiben, Mycocure, MycofinNail dermatophytes āύāĻŋāĻ°ā§āĻŽā§‚āϞ
5Selected superficial fungal infectionClotrimazole 1%Clarizol, DermasimTopical antifungal
6Confirmed susceptible bacterial infectionCefiximeCefim-3 DS, Cef-3 DSāύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ bacterial infection; routine scabies therapy āύ⧟
7Selected inflammatory dermatosisMethylprednisoloneSolupred, DepomedSteroid-responsive inflammation; routine scabies therapy āύ⧟
8Selected infected inflammatory dermatosisBetamethasone + Clotrimazole + GentamicinCombiderm, Bet-CGāϕ⧇āĻŦāϞ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ indication-āĻ; indiscriminate use āύ⧟

āĻāχ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāϗ⧁āϞ⧋ MedEx-āĻāϰ generic āĻ“ brand listings āĻĨ⧇āϕ⧇ āύ⧇āĻ“ā§ŸāĻžāĨ¤ Scabies āĻŦāĻž nail fungus-āĻāϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟, disease severity, contraindication āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ investigation āĻ…āύ⧁āϝāĻžā§Ÿā§€ medication āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.96


🟨 SECTION 09 — My Clinical Working Assessment / āφāĻŽāĻžāϰ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

đŸŸĒ 9.1 Prescription-Ready Provisional Diagnosis / āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻžāϰ āωāĻĒāϝ⧋āĻ—ā§€ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Recommended diagnostic note:

Dx: Suspected Scabies (B86), with possible associated Pruritic Dermatitis; R/O Onychomycosis (B35.1). Secondary bacterial infection not established.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻŦāĻž āĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻž, āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚ⧁āϞāĻ•āĻžāύāĻŋāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš; āύāϖ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒāĻ°ā§āϝāĻžā§Ÿā§‡āϰ āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋ⧟āĻžāϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Confidence: Scabies 0.70 | Onychomycosis 0.72 | Secondary dermatitis 0.62

đŸŸĒ 9.2 Specific Specialist Referral / āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžā§‡āϰ āĻ•āĻžāϛ⧇ āϰ⧇āĻĢāĻžāϰ

Primary referral: Dermatologist / āϚāĻ°ā§āĻŽ āĻ“ āϝ⧌āύāϰ⧋āĻ— āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

Referral note: Suspected scabies with possible nail dermatophytosis; evaluate need for systemic antifungal, confirm diagnosis and review non-standard multidrug regimenāĨ¤

āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻ“ āύāϖ⧇āϰ fungal infection āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇, systemic antifungal āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ•āĻŋ āύāĻž āĻāĻŦāĻ‚ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ“āώ⧁āϧ⧇āϰ āĻĄā§‹āϜ āĻ“ duration āύāĻŋāϰāĻžāĻĒāĻĻ āĻ•āĻŋ āύāĻž āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Referral confidence: 0.99

🟧 9.3 Clinical Diagnostic Conclusion / āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āωāĻĒāϏāĻ‚āĻšāĻžāϰ

Most likely treatment target: Scabies.

Probable concurrent condition: Onychomycosis.

Unconfirmed conditions: Bacterial skin infection, alopecia disorder, severe inflammatory dermatitis.

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻāĻ•āχ āϏāĻ™ā§āϗ⧇ scabicidal, antifungal, antihistamine, steroid āĻāĻŦāĻ‚ antibiotic therapy āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āĻāϰ āĻĢāϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻāĻ•āĻžāϧāĻŋāĻ• āϚāĻ°ā§āĻŽāϰ⧋āϗ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ•āϰāϛ⧇āύ āĻŦāϞ⧇ āϧāĻžāϰāĻŖāĻž āĻšā§Ÿ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒā§āϰāϤāĻŋāϟāĻŋ āϰ⧋āϗ⧇āϰ objective evidence āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

Overall diagnostic confidence: 0.70

9.4 Doctor’s Dx vs My Dx — Clinical Comparison

ComparisonDoctor’s documented DxMy assessmentAgreement
Scabies“IS”; meaning unclearSuspected scabiesđŸŸĸ Treatment pattern supports
OnychomycosisPossible “Ony”Possible onychomycosisđŸŸĸ Probable
Pruritic dermatitisNot explicitly documentedPossible🟠 Inferred
Secondary bacterial infectionNot explicitly documentedNot confirmed🟠 Insufficient evidence
Hair disorderNot documentedUndetermined🟠 No diagnosis possible

đŸŸĸ Similarity / āĻŽāĻŋāϞ

Doctor’s medication selection āĻāĻŦāĻ‚ āφāĻŽāĻžāϰ working assessment—āωāĻ­ā§Ÿā§‡āχ scabies āĻāĻŦāĻ‚ possible nail fungal infection-āĻāϰ āĻĻāĻŋāϕ⧇ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰāϛ⧇āĨ¤

🟠 Dissimilarity / āĻ…āĻŽāĻŋāϞ

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŦā§āϝāĻŦāĻšā§ƒāϤ “IS” abbreviation-āĻāϰ āĻ…āĻ°ā§āĻĨ āĻ¸ā§āĻĒāĻˇā§āϟ āύ⧟āĨ¤ āϤāĻžāχ physician-confirmed scabies diagnosis āĻĻāĻžāĻŦāĻŋ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤ āĻāĻ›āĻžā§œāĻž āĻ•āĻŋāϛ⧁ medication regimen routine guideline-based treatment āĻĨ⧇āϕ⧇ āĻ­āĻŋāĻ¨ā§āύ; āĻāϗ⧁āϞ⧋ āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Comparison confidence: 0.82 for treatment intent; 0.60 for actual disease concordance.


đŸŸĻ SECTION 10 — Disease Definition / āϰ⧋āϗ⧇āϰ āϏāĻ‚āĻœā§āĻžāĻž

10.1 Scabies / āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āϕ⧀?

Definition: Scabies is a contagious parasitic skin infestation caused by Sarcoptes scabiei var. hominis.

āĻŦāĻžāĻ‚āϞāĻž: āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻšāϞ⧋ Sarcoptes scabiei āύāĻžāĻŽā§‡āϰ āĻ…āϤāĻŋāĻ•ā§āώ⧁āĻĻā§āϰ āĻĒāϰāĻœā§€āĻŦā§€ āĻŽāĻžāχāϟ āĻĻā§āĻŦāĻžāϰāĻž āϏ⧃āĻˇā§āϟ āϏāĻ‚āĻ•ā§āϰāĻžāĻŽāĻ• āϚāĻ°ā§āĻŽāϰ⧋āĻ—āĨ¤

āĻāχ āĻŽāĻžāχāϟ āĻ¤ā§āĻŦāϕ⧇āϰ āωāĻĒāϰāĻŋāĻ­āĻžāϗ⧇ āϏ⧁āĻĄāĻŧāĻ™ā§āĻ— āϤ⧈āϰāĻŋ āĻ•āϰ⧇ āĻāĻŦāĻ‚ immune reaction-āĻāϰ āĻ•āĻžāϰāϪ⧇ āϤ⧀āĻŦā§āϰ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

10.2 Onychomycosis / āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϕ⧀?

Definition: Onychomycosis is a fungal infection involving the nail plate, nail bed or nail matrixāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āύāϖ⧇āϰ āĻĒā§āϞ⧇āϟ, āύāĻŋāĻšā§‡āϰ āĻ…āĻ‚āĻļ āĻŦāĻž āύāĻ– āϤ⧈āϰāĻŋāϰ āĻ…āĻ‚āĻļ⧇ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖāϕ⧇ Onychomycosis āĻŦāϞ⧇āĨ¤

āύāĻ– āĻŽā§‹āϟāĻž āĻšāĻ“ā§ŸāĻž, āĻ­āĻ™ā§āϗ⧁āϰ āĻšāĻ“ā§ŸāĻž, āĻšāϞ⧁āĻĻ āĻŦāĻž āϏāĻžāĻĻāĻž āϰāĻ‚ āϧāĻžāϰāĻŖ āĻ•āϰāĻž āĻāĻŦāĻ‚ nail plate āφāϞāĻ—āĻž āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦ⧈āĻļāĻŋāĻˇā§āĻŸā§āϝāĨ¤

Confidence: 0.99


đŸŸĻ SECTION 11 — Etiology & Pathophysiology / āϰ⧋āϗ⧇āϰ āĻ•āĻžāϰāĻŖ āĻ“ āϰ⧋āĻ—āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

Scabies

Etiology / āĻ•āĻžāϰāĻŖ: Sarcoptes scabiei var. hominis miteāĨ¤

Pathophysiology / āϰ⧋āĻ—āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž: āĻŽāĻžāχāϟ āĻ¤ā§āĻŦāϕ⧇āϰ stratum corneum āĻ¸ā§āϤāϰ⧇ āĻĒā§āϰāĻŦ⧇āĻļ āĻ•āϰ⧇āĨ¤ Mite antigen, eggs āĻ“ faecal material-āĻāϰ āĻŦāĻŋāϰ⧁āĻĻā§āϧ⧇ delayed hypersensitivity reaction āϤ⧈āϰāĻŋ āĻšā§ŸāĨ¤ āĻĢāϞ⧇ pruritus, papules āĻ“ inflammatory skin lesions āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Onychomycosis

Etiology / āĻ•āĻžāϰāĻŖ: Dermatophytes, āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ Trichophyton rubrum; āĻāĻ›āĻžā§œāĻž yeasts āĻ“ āĻ•āĻŋāϛ⧁ non-dermatophyte mouldsāĨ¤

Pathophysiology: Fungal organisms nail keratin-āĻ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰ⧇āĨ¤ āĻĢāϞ⧇ nail discoloration, thickening, subungual debris āĻāĻŦāĻ‚ onycholysis āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Confidence: 0.97


đŸŸĻ SECTION 12 — Clinical Features / āϰ⧋āϗ⧇āϰ āϞāĻ•ā§āώāĻŖāϏāĻŽā§‚āĻš

DiseaseClinical featureāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ
ScabiesNocturnal pruritusāϰāĻžāϤ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻŦ⧇āĻļāĻŋ
ScabiesPapular eruptionāϛ⧋āϟ āωāρāϚ⧁ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋ
ScabiesBurrowsāĻ¤ā§āĻŦāϕ⧇ āϏāϰ⧁ āϏ⧁āĻĄāĻŧāĻ™ā§āϗ⧇āϰ āĻŽāϤ⧋ āĻĻāĻžāĻ—
ScabiesInterdigital involvementāφāϙ⧁āϞ⧇āϰ āĻĢāĻžāρāϕ⧇ āĻ•ā§āώāϤ
ScabiesHousehold clusteringāĻāĻ•āχ āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻāĻ•āĻžāϧāĻŋāĻ• āĻŦā§āϝāĻ•ā§āϤāĻŋāϰ āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻšāĻ“ā§ŸāĻž
OnychomycosisNail thickeningāύāĻ– āĻŽā§‹āϟāĻž āĻšāĻ“ā§ŸāĻž
OnychomycosisNail discolorationāύāϖ⧇āϰ āϰāĻ‚ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
OnychomycosisSubungual hyperkeratosisāύāϖ⧇āϰ āύāĻŋāĻšā§‡ āϕ⧇āϰāĻžāϟāĻŋāύ āϜāĻŽāĻž
OnychomycosisOnycholysisāύāϖ⧇āϰ āĻĒā§āϞ⧇āϟ āφāϞāĻ—āĻž āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻž

Important: āĻāχ āϞāĻ•ā§āώāĻŖāϗ⧁āϞ⧋āϰ āĻ…āϧāĻŋāĻ•āĻžāĻ‚āĻļāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ documented āύ⧟; āĻāϗ⧁āϞ⧋ āϰ⧋āĻ— āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ⧇āϰ āϏāĻŽā§Ÿ āϖ⧁āρāϜāϤ⧇ āĻšāĻŦ⧇āĨ¤

Confidence: 0.98


đŸŸĻ SECTION 13 — Differential Diagnosis / āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Differential diagnosisāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨDistinguishing findings
ScabiesāĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻžNight itching, burrows, affected contacts
Atopic dermatitisāĻ…ā§āϝāĻžāĻŸā§‹āĻĒāĻŋāĻ• āĻāĻ•āϜāĻŋāĻŽāĻžChronic relapsing eczema, typical distribution
Allergic contact dermatitisāϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļāϜāύāĻŋāϤ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āĻĒā§āϰāĻĻāĻžāĻšRelevant exposure and distribution
Tinea corporisāĻļāϰ⧀āϰ⧇āϰ āĻĻāĻžāĻĻAnnular scaly plaques
Papular urticariaāĻĒā§‹āĻ•āĻžāĻŽāĻžāĻ•ā§œā§‡āϰ āĻ•āĻžāĻŽā§œā§‡ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋExposure-related grouped papules
Onychomycosisāύāϖ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•Mycological evidence
Nail psoriasisāύāϖ⧇āϰ āϏ⧋āϰāĻŋ⧟āĻžāϏāĻŋāϏPitting, oil spots, onycholysis

Most important differential question: āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻ“ skin lesions-āĻāϰ āĻĒā§āϰāĻ•ā§ƒāϤ pattern āĻ•āĻŋ classic scabies-āĻāϰ āϏāĻ™ā§āϗ⧇ āĻŽā§‡āϞ⧇, āύāĻžāĻ•āĻŋ eczema āĻŦāĻž fungal dermatitis-āĻāϰ āϏāĻ™ā§āϗ⧇?

Confidence: 0.94


đŸŸĻ SECTION 14 — Investigation Interpretation / āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž

āĻāχ āϕ⧇āϏ⧇ āϕ⧋āύ⧋ laboratory report āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋāĨ¤ āϤāĻžāχ āύāĻŋāĻšā§‡āϰ āĻ…āĻ‚āĻļāϟāĻŋ proposed interpretation framework, āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰāĻ•ā§ƒāϤ āĻĢāϞāĻžāĻĢāϞ āύ⧟āĨ¤

TestPossible resultClinical interpretation
Skin scraping microscopyMite, eggs or faecal pellets foundScabies diagnosis supported
DermoscopyCharacteristic mite/burrow signScabies strongly supported
Nail KOHFungal hyphae foundNail fungal infection supported
Nail culture/PASFungal elements or organism identifiedOnychomycosis diagnosis strengthened
ALT/ASTElevatedTerbinafine safety assessment required
BilirubinElevatedHepatic assessment required

Clinical limitation: Nail discoloration alone cannot distinguish fungal infection from psoriasis, trauma or other nail disorders. Similarly, treatment with Permethrin does not establish a positive scabies test.

Confidence: 0.98


đŸŸĻ SECTION 15 — Management & Treatment — Guideline-Based Approach / āĻ—āĻžāχāĻĄāϞāĻžāχāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

15.1 Scabies Management / āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

CDC āĻ…āύ⧁āϝāĻžā§Ÿā§€ classic scabies-āĻāϰ standard treatments-āĻāϰ āĻŽāĻ§ā§āϝ⧇ āĻ°ā§Ÿā§‡āϛ⧇:

Permethrin 5% cream: Adult patient-āĻ āĻ—āϞāĻž āĻĨ⧇āϕ⧇ āĻĒāĻžā§Ÿā§‡āϰ āφāϙ⧁āϞ āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻ¤ā§āĻŦāϕ⧇ āĻĒā§āĻ°ā§Ÿā§‹āĻ—, 8–14 āϘāĻŖā§āϟāĻž āĻĒāϰ⧇ āĻ§ā§ā§Ÿā§‡ āĻĢ⧇āϞāĻž; āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ āĻĒā§āϰāĻžā§Ÿ āĻāĻ• āϏāĻĒā§āϤāĻžāĻš āĻĒāϰ⧇ āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ applicationāĨ¤

Ivermectin: 200 micrograms/kg per dose, āϏāĻžāϧāĻžāϰāĻŖāϤ 7–14 āĻĻāĻŋāύ⧇āϰ āĻŦā§āϝāĻŦāϧāĻžāύ⧇ āĻĻ⧁āχ āĻĄā§‹āϜāĨ¤ āĻ“āϜāύāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āĻĄā§‹āϜ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Contact management: āĻāĻ•āχ household-āĻāϰ close contacts-āĻĻ⧇āϰ āĻāĻ•āϏāĻ™ā§āϗ⧇ evaluation/treatment; āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ•āĻžāĻĒ⧜, āĻŦāĻŋāĻ›āĻžāύāĻžāϰ āϚāĻžāĻĻāϰ āĻ“ āĻ¤ā§‹ā§ŸāĻžāϞ⧇ hot washing/drying; āĻ§ā§‹ā§ŸāĻž āϝāĻžā§Ÿ āύāĻž āĻāĻŽāύ āϜāĻŋāύāĻŋāϏ āĻ•ā§Ÿā§‡āĻ• āĻĻāĻŋāύ āϏāĻŋāϞ āĻ•āϰāĻžāĨ¤

Post-scabetic itch: āϏāĻĢāϞ treatment-āĻāϰ āĻĒāϰāĻ“ āĻ•ā§Ÿā§‡āĻ• āϏāĻĒā§āϤāĻžāĻš āϚ⧁āϞāĻ•āĻžāύāĻŋ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻļ⧁āϧ⧁ residual itching-āĻāϰ āĻ•āĻžāϰāϪ⧇ āĻŦāĻžāϰāĻŦāĻžāϰ scabicide āĻŦā§āϝāĻŦāĻšāĻžāϰ āωāĻĒāϝ⧁āĻ•ā§āϤ āύ⧟āĨ¤

15.2 Onychomycosis Management / āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāϕ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž

Confirm fungal infection: Nail clipping, KOH, PAS āĻŦāĻž cultureāĨ¤

Assess liver function: Oral terbinafine-āĻāϰ āφāϗ⧇ liver disease history āĻ“ baseline transaminasesāĨ¤

Systemic antifungal: Confirmed dermatophyte nail infection-āĻ Terbinafine 250 mg/day āϏāĻžāϧāĻžāϰāĻŖāϤ fingernail-āĻāϰ āϜāĻ¨ā§āϝ 6 weeks, toenail-āĻāϰ āϜāĻ¨ā§āϝ 12 weeksāĨ¤

Follow-up: Clinical response āύāϖ⧇āϰ āύāϤ⧁āύ āĻŦ⧃āĻĻā§āϧāĻŋ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϧ⧀āϰ⧇ āĻĻ⧇āĻ–āĻž āϝāĻžā§ŸāĨ¤ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ liver-function monitoringāĨ¤

Confidence: 0.97

15.3 Critical Review of This Prescription / āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻ¤ā§āϰ⧁āϟāĻŋ āĻŦāĻž āϝāĻžāϚāĻžāĻ‡ā§Ÿā§‡āϰ āĻŦāĻŋāώ⧟

ConcernClinical significanceRecommended response
Cefixime 800 mg/dayAbove usual adult daily doseVerify prescription and indication
Ivermectin 12 mg alternate-day ×5Non-standard for uncomplicated scabiesCheck body weight, diagnosis and severity
Permethrin on 5 nightsMore intensive than routine treatmentExclude crusted scabies; confirm schedule
MethylprednisoloneNot routine scabies treatmentReassess steroid indication
Combiderm for 1 monthProlonged steroid-combination exposureReview duration and application sites
Terbinafine for 2 monthsRequires fungal confirmation and liver assessmentCheck nail site, KOH/PAS, ALT/AST
Nailcis/ReonaAdjunctive cosmetic productsDo not assume proven disease-modifying efficacy

Safety review confidence: 0.98


đŸŸĻ SECTION 16 — Clinical Prescription Demo, Overview & Actionable Plan / āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύāĻŽā§āύāĻž, āϏāĻžāϰāϏāĻ‚āĻ•ā§āώ⧇āĻĒ āĻ“ āĻ•āϰāĻŖā§€ā§Ÿ

16.1 Clinical Prescription Demo / āύāĻŽā§āύāĻž āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ

Educational documentation example only — āĻāϟāĻŋ āύāϤ⧁āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āφāĻĻ⧇āĻļ āύ⧟āĨ¤

Patient: 28 years

Date: 21/10/2026

Department: Dermatology

C/C: Not documented in source prescription; clarify pruritus, rash distribution, duration and nail symptomsāĨ¤

O/E: Pending clinical examinationāĨ¤

Provisional Dx:

1. Suspected Scabies — B86

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻŦāĻž āĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻžāĨ¤

2. R/O Onychomycosis — B35.1

āύāϖ⧇ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āφāϛ⧇ āĻ•āĻŋ āύāĻž āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰ⧇ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

3. Possible Pruritic Dermatitis

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚ⧁āϞāĻ•āĻžāύāĻŋāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤

Investigations:

  • Dermatological examination Âą dermoscopyāĨ¤
  • Nail KOH microscopy Âą fungal culture/PASāĨ¤
  • ALT/AST before oral terbinafineāĨ¤
  • Additional investigations according to examinationāĨ¤

Rx review: Original medications reconciled; do not reproduce potentially inappropriate dosing without direct prescriber confirmationāĨ¤

Advice: Household contact evaluation, skin hygiene, avoid unnecessary steroid use, return for medication safety reviewāĨ¤

Follow-up: Dermatology review promptly, particularly before continuing oral antibiotic, multiple-dose ivermectin or systemic antifungal treatmentāĨ¤

16.2 Overview / āϏāĻžāϰāϏāĻ‚āĻ•ā§āώ⧇āĻĒ

Most likely clinical interpretation: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ nail fungal disease-āĻāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻ•āϰāϤ⧇ āĻšā§‡ā§Ÿā§‡āϛ⧇āύāĨ¤

What remains unconfirmed: āϰ⧋āĻ—ā§€āϰ actual lesions, fungal diagnosis, secondary bacterial infection āĻ“ hair-loss disorderāĨ¤

Highest-priority issue: āĻ•ā§Ÿā§‡āĻ•āϟāĻŋ medication regimen standard recommendations āĻĨ⧇āϕ⧇ āĻ­āĻŋāĻ¨ā§āύ; dose āĻāĻŦāĻ‚ indication āϝāĻžāϚāĻžāχ āĻ…āĻĒāϰāĻŋāĻšāĻžāĻ°ā§āϝāĨ¤

Overall assessment confidence: 0.70

16.3 Actionable Plan / āĻ•āϰāĻŖā§€ā§Ÿ

  1. Within the next clinical review: Dermatologist āĻĻāĻŋā§Ÿā§‡ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ skin āĻ“ nail examination āĻ•āϰāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤
  2. Before continuing questionable regimens: Cefixime, Ivermectin āĻ“ Permethrin-āĻāϰ dose/schedule āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤
  3. Before systemic antifungal treatment: Nail fungal confirmation āĻāĻŦāĻ‚ baseline LFT āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤
  4. During follow-up: āύāϤ⧁āύ burrows, rash, fever, pus, spreading redness, jaundice āĻŦāĻž significant adverse effects āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤
  5. Household management: Scabies clinically supported āĻšāϞ⧇ close contacts āĻ“ bedding/clothing management āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Action-plan confidence: 0.98


đŸŸĻ SECTION 17 — References — Textbooks, Guidelines & Peer-Reviewed Journals / āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

A. Standard Medical Textbooks / āĻĒā§āϰāĻžāĻŽāĻžāĻŖā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĻŦāĻŋāĻœā§āĻžāĻžāύ āĻŦāχ

  1. Andrews’ Diseases of the Skin: Clinical Dermatology. 14th edition. Elsevier. Relevant topics: Parasitic infestations, superficial fungal infections and inflammatory dermatosesāĨ¤
  2. Davidson’s Principles and Practice of Medicine. 24th edition. Elsevier. Dermatology section: Common skin infections and infestationsāĨ¤
  3. Harrison’s Principles of Internal Medicine. 22nd edition. McGraw Hill. Relevant topics: Ectoparasitic infestation and dermatophyte infectionsāĨ¤
  4. Katzung’s Basic & Clinical Pharmacology. 16th edition. McGraw Hill. Relevant topics: Antimicrobial, antiparasitic, antihistamine and corticosteroid pharmacologyāĨ¤
  5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th edition. McGraw Hill. Relevant topics: Antifungal and antiparasitic medicationsāĨ¤

āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ edition-āĻāϰ page number āϏāϰāĻžāϏāϰāĻŋ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšā§ŸāύāĻŋ; āϤāĻžāχ āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰ⧇ page number āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋāĨ¤

B. Clinical Guidelines / āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāĻ•āĻž

1. CDC — Clinical Care of Scabies (2023).

Permethrin āĻāĻŦāĻ‚ Ivermectin-āĻāϰ recommended use, dosage and repeat-treatment scheduleāĨ¤

2. CDC — Preventing Scabies (2023).

Household contact treatment, washing and environmental measuresāĨ¤

3. Nenoff P, et al. S1 Guideline on Onychomycosis (2023).

Fungal confirmation, systemic treatment āĻāĻŦāĻ‚ antifungal-associated liver monitoringāĨ¤

C. Peer-Reviewed Journals with DOI / DOI-āϏāĻš āĻ—āĻŦ⧇āώāĻŖāĻžāĻĒāĻ¤ā§āϰ

1. Uzun S, et al. Clinical practice guidelines for the diagnosis and treatment of scabies. International Journal of Dermatology. 2024;63(12):1642–1656.

DOI: 10.1111/ijd.17327

Read journal article

2. Nenoff P, et al. S1 Guideline onychomycosis. Journal der Deutschen Dermatologischen Gesellschaft. 2023.

DOI: 10.1111/ddg.14988

Read journal article

D. Bangladesh Drug Database / āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇āϰ āĻ“āώ⧁āϧ⧇āϰ āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

MedEx Bangladesh: Cefim-3 DS, Atrizin, Alice, Solupred, Combiderm combination, Clarizol, Fungiben āĻāĻŦāĻ‚ Perosa-āĻāϰ generic, composition, therapeutic class, dosage āĻ“ listed price āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ Cosmetic products-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ MedEx listing āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋ; āϏ⧇āϗ⧁āϞ⧋āϰ āϤāĻĨā§āϝ āĻĒ⧃āĻĨāĻ• product sources āĻĨ⧇āϕ⧇ āύ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Drug-information confidence: 0.96


Final Clinical Working Diagnosis / āĻšā§‚ā§œāĻžāĻ¨ā§āϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Suspected Scabies with Possible Onychomycosis and Associated Pruritic Dermatitis.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ–ā§‹āϏāĻĒāĻžāρāϚ⧜āĻž, āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āύāϖ⧇āϰ āĻ›āĻ¤ā§āϰāĻžāĻ•āϜāύāĻŋāϤ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻ“ āϚ⧁āϞāĻ•āĻžāύāĻŋāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤

Diagnostic status: Provisional — not confirmed.

Overall confidence score: 0.70/1.00

Author: Md. Rafiqul Islam Lipu

Publication Series: LIPU MED

Website: Raiyyantahsan.com

Date: Wednesday, 21 October 2026

Time: 12:36 PM (Bangladesh Standard Time, UTC+06:00)

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top